These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1996556)

  • 1. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID).
    Lopez-Fernandez MF; Gonzalez-Boullosa R; Blanco-Lopez MJ; Perez M; Batlle J
    Am J Hematol; 1991 Mar; 36(3):163-70. PubMed ID: 1996556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.
    Casonato A; Pontara E; Bertomoro A; Dannhauser D; Secchiero S; Zaninotto M; Girolami A
    Ann Hematol; 1995 Oct; 71(4):189-94. PubMed ID: 7578526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals.
    Batlle J; Lopez-Fernandez MF; Lopez-Borrasca A; Lopez-Berges C; Dent JA; Berkowitz SD; Ruggeri ZM; Zimmerman TS
    Blood; 1987 Jul; 70(1):173-6. PubMed ID: 3496131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolytic processing of von Willebrand factor subunit: heterogeneity in type-IIA von Willebrand disease.
    Batlle J; Lasierra J; Villamor AF; Navarro JL; Pardo A; Campos M; Justiça B; López Fernández MF
    Ann Hematol; 1994 Mar; 68(3):111-5. PubMed ID: 8167176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.
    Pérez-Rodríguez A; García-Rivero A; Lourés E; López-Fernández MF; Rodríguez-Trillo A; Batlle J
    Haematologica; 2009 May; 94(5):679-86. PubMed ID: 19286880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC).
    Ciavarella G; Ciavarella N; Antoncecchi S; De Mattia D; Ranieri P; Dent J; Zimmerman TS; Ruggeri ZM
    Blood; 1985 Dec; 66(6):1423-9. PubMed ID: 3877533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.
    Mannucci PM; Lombardi R; Castaman G; Dent JA; Lattuada A; Rodeghiero F; Zimmerman TS
    Blood; 1988 Jan; 71(1):65-70. PubMed ID: 3257148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.
    Mannucci PM; Lombardi R; Bader R; Vianello L; Federici AB; Solinas S; Mazzucconi MG; Mariani G
    Blood; 1985 Oct; 66(4):796-802. PubMed ID: 3876122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor.
    Castaman G; Rodeghiero F; Lattuada A; Mannucci PM
    Thromb Res; 1992 Feb; 65(3):343-51. PubMed ID: 1631800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmopressin-induced thrombocytopenia in type I platelet discordant von Willebrand disease.
    Castaman G; Rodeghiero F; Lattuada A; Mannucci PM
    Am J Hematol; 1993 May; 43(1):5-9. PubMed ID: 8317462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
    Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.